US regulators have approved the first drug to treat adults and children with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets.
News
Final NHS nod for Roche’s RoActemra
Roche/Chugai’s RoActemra should be routinely offered throughout the NHS to adults with giant cell arteritis (GCA) within the next three months, following a final green light from cost regulators.
GW’s Epidiolex takes a leap toward US approval
Shares in GW Pharma were given a boost after its cannabinoid Epidiolex took a giant leap towards US approval for treating seizures linked with Lennox-Gastaut (LGS) and Dravet syndromes.
MPs slate rate of progress on NHS cyber security
MPs have criticised the government’s slow response to last year’s WannaCry attack on the NHS, and warn there is much work to be done to improve cyber security if damage from the next attack is to be minimised.
GSK picks Kevin Sim to lead business development for pharma R&D
GlaxoSmithKline has named Kevin Sim as senior vice president and head of worldwide business development for pharmaceuticals R&D.
CR UK, AACR form international cancer alliance
Cancer Research UK and the American Association for Cancer Research (AACR) are launching a new international alliance dedicated to accelerating progress against cancer.
Rigel bags first FDA approval
Rigel Pharmaceuticals has bagged its first FDA approval, with a green light to market Tavalisse for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have failed to respond to previous treatment.
US expands use of Shire’s Vonvendi
US regulators have expended the scope of Shire’s Vonvendi to include perioperative management of bleeding in adults with von Willebrand disease (VWD).
Amgen, Novartis’ migraine therapy impresses again
Amgen and Novartis’ closely watched experimental migraine therapy Aimovig has impressed again in late stage trials, this time hitting targets in patients for which other preventative treatments failed to work or weren’t tolerated.
BMS’ Opdivo/Yervoy combo cleared for kidney cancer
US regulators have approved a combination of Bristol-Myers Squibb’s immunotherapy drugs Opdivo and Yervoy as a first-line treatment for patients with advanced renal cell carcinoma.
Keytruda/chemo combo cut risk of death in NSCLC
MSD has unveiled further data from a trial showing that a combination of Keytruda and chemotherapy significantly improved overall survival in patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
Oxford Uni, Boehringer, Lilly link to test Jardiance in kidney disease
Boehringer Ingelheim and Eli Lilly are linking with Oxford University to assess the effect of SGLT2 inhibitor Jardiance on kidney disease and cardiovascular death.
BMS ties with Janssen on Factor XIa inhibitor programme
Bristol-Myers Squibb and Johnson & Johnson group Janssen have announced a deal to work together on a Factor XIa (FXIa) inhibitor programme.
Sanofi to sell generics unit for 1.9 billion Euros
Global investment group Advent International says it has entered into exclusive negotiations to buy Sanofi’s generics arm Zentiva for 1.9 billion Euros ($2.4 billion).
AZ’ Tagrisso offers sustained benefit in lung cancer
AstraZeneca says that the “unprecedented progression-free survival benefit” of Tagrisso when used as a first line treatment for lung cancer is sustained through subsequent lines of therapy.
